Results from this prospective study in a Japanese population confirm an effect of the 21-gene assay results on adjuvant treatment decision-making, consistent with reported experiences from the United States and Europe.

No abstract

No abstract

With quality adjustment, RRM, RRSO, and RRM&RRSO were all cost-effective preventive strategies in BRCA1/2 mutation carriers, with RRM&RRSO being the most cost-effective in BRCA1 and RRM in BRCA2. This result supports the inclusion of insurance coverage for BRCA mutation carriers in Japan.

In Japan, breast cancer was considered the leading cause for cost of work loss, and the most influential cause when the product of the "employment rate coefficient × productivity coefficient" for breast cancer was assumed the same as the product for all other types of cancers. It is necessary to establish support systems for working cancer survivors.